Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
Calliditas Therapeutics AB
Richard Lafayette; Jens Kristensen; Andrew Stone; Jürgen Floege; Vladimir Tesař; Hernán Trimarchi; Hong Zhang; Necmi Eren; Alexander Paliege; Heather N Reich; Brad H Rovin; Jonathan Barratt; NefIgArd trial investigators
Stone Biostatistics, Crewe, UK.